-

01:57:21 AM

SLRX Stock News

SLRX - Salarius Pharmaceuticals Inc

09/28/21 7:01 AM

Nasdaq : SLRX

Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced the receipt of a $2.7

RHEA-AI

very positive

09/27/21 8:03 AM

Nasdaq : SLRX

conferences

Salarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief

RHEA-AI

neutral

09/22/21 7:33 AM

Nasdaq : SLRX

partnership

Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership

Salarius Pharmaceuticals Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced a research partnership

RHEA-AI

neutral

09/20/21 7:33 AM

Nasdaq : SLRX

Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced its inclusion in the FTSE

RHEA-AI

neutral

09/15/21 8:03 AM

Nasdaq : SLRX

conferences

Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief

RHEA-AI

neutral

09/08/21 8:13 AM

Nasdaq : SLRX

conferences

Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief

RHEA-AI

neutral

08/12/21 2:00 PM

Nasdaq : SLRX

conferences

Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief

RHEA-AI

neutral

08/05/21 7:32 AM

Nasdaq : SLRX

earnings

Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

Clinical Trial in Hematologic Cancers Initiated and Initial Patients Enrolled in Expanded Sarcoma Clinical Trial; Multiple Potential Data Readouts Expected in 2021 and 2022 Preliminary Efficacy Findings from Sarcoma and Advanced Solid Tumor Trials Presented at American Society of Clinical Oncology

RHEA-AI

neutral

07/29/21 7:33 AM

Nasdaq : SLRX

conferencesearnings

Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,

RHEA-AI

neutral

07/14/21 8:05 AM

Nasdaq : SLRX

conferences

Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets Summit

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 Next

SLRX Data

IndustryPharmaceutical Preparation Manufacturing
Websitesalariuspharma.com
CeoDavid Arthur
Security nameSalarius Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees8
Tags
- Health Technology
- Pharmaceuticals: Other
- Commercial Services
- Miscellaneous Commercial Services
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2450 Holcombe Blvd Ste J-608
StateTexas
CityHouston
Zip77021-2041
CountryUS
Phone13467720346

About Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius' lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and Ewing-related sarcomas, also called FET-translocated sarcomas. Ewing sarcoma has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT).